Clinical trials: Locoregional Neoplasm Recurrence
Colon Cancer
Regional Anesthesia in Colon Rectal Surgery
This study will compare recurrence rates in patients with colorectal cancer who will be randomly assigned to epidural anesthesia/analgesia combined with general anesthesia or to general anesthesia followed by opioid analgesia.
- Trial name
- NCT00684229
- Testing
- Regional anesthesia and analgesia, general anesthesia followed by opioid analgesia
- Where
- 3 sites in United States, Argentina and 1 more
- Sponsor
- The Cleveland Clinic
Colorectal Carcinoma, Renal Cancer
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE)…
- Conditions
- Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- PELFIRE (NCT07782164)
- Testing
- Irreversible electroporation
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- Amsterdam UMC, location VUmc
Prostate Cancer
Single Fraction Early Prostate Irradiation (SiFEPI)
Recently, HDR brachytherapy delivering only a 19 Gy fraction was proposed as exclusive treatment for low and intermediate risk prostate cancers.
- Trial name
- SiFEPI (NCT02104362)
- Testing
- exclusive single-fraction irradiation
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
Recurrent Nasopharyngeal Carcinoma
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
The purpose of this study is to evaluate the efficacy and safety of chemotherapy with Lobaplatin and 5-FU, in Recurrent Local or Distant Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03210389
- Testing
- Lobaplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Neuroblastoma
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
RATIONALE: Beta-glucan may stimulate the immune system and stop tumor cells from growing. Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00492167
- Testing
- beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anal Cancer, Rectal Cancer
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma…
- Trial name
- NCT02399813
- Testing
- Axalimogene filolisbac
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Advaxis, Inc.
Neuroblastoma
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor killing substances to them without harming normal cells.
- Trial name
- NCT00004110
- Testing
- monoclonal antibody 3F8, etoposide, isotretinoin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, High-grade Glioma
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent…
- Conditions
- Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
- Trial name
- DUAL-CAR-NK-GB (NCT07480941)
- Testing
- Dual-target CAR-NK cells, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Breast Cancer
Radiotherapy After Primary Chemotherapy for Breastcancer
The primary aim of the study is to evaluate the 5 yr locoregional recurrence rate (LRR) in cT1-2cN0-1(cytology/histology and/or positive SN, excluding patients with > 3 pathologic axillary nodes on imaging) breast cancer…
- Trial name
- RAPCHEM (NCT01279304)
- Testing
- radiation - no radiation see intervention description, radiation: see intervention description
- Where
- 6 sites in Netherlands
- Volunteers
- 851 people
- Sponsor
- Maastricht Radiation Oncology
Neuroblastoma
N99-02: Melphalan and Buthionine Sulfoximine
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- BSO (NCT00005835)
- Testing
- buthionine sulfoximine, melphalan, Peripheral blood stem cell infusion
- Where
- 9 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Breast Cancer, Sentinel Lymph Node
Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients
In patients undergoing breast-conserving surgery and having positive sentinel lymph nodes (SLNs), the ACOSOG Z0011 trial showed equivalent overall survival(OS) and disease-free survival(DFS) outcomes for patients receiving SLN…
- Conditions
- Breast Cancer, Sentinel Lymph Node, Local Recurrence of Malignant Tumor of Breast
- Trial name
- NCT03606616
- Testing
- no further ALND arm
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Peking University People's Hospital
Liver Neoplasms, Liver Cirrhosis
Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
Besides liver transplantation, the curative treatment of primary hepatic cancer with cirrhosis remains the surgical resection. Radiofrequency or cryotherapy currently allow local ablation of small cancer, with very good results.
- Conditions
- Liver Neoplasms, Liver Cirrhosis, Carcinoma, Hepatocellular, Recurrence
- Trial name
- GEMOXIAL (NCT00470340)
- Testing
- Oxaliplatin, gemcitabine, cisplatin, lipiodol
- Where
- France
- Volunteers
- 263 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Cancer, Thoracic Surgery
Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery
Available studies suggest that regional anesthesia-analgesia may decrease the occurrence of recurrence/metastasis in patients after cancer surgery. However, evidences from prospective studies are still lacking.
- Conditions
- Lung Cancer, Thoracic Surgery, Anesthesia, Epidural, Neoplasm Recurrence, Local
- Trial name
- NCT02801409
- Testing
- General anesthesia alone, Combined epidural-general anesthesia
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking University First Hospital
Breast Carcinoma
Intraoperative Radiotherapy After Local Recurrence in Breast Cancer
The investigators propose a prospective, multicenter, single arm Phase II design to evaluate the feasibility of repeated breast-conserving surgery combined with re- irradiation using IORT after local recurrence of breast…
- Trial name
- RE-IORT01 (NCT02386371)
- Testing
- tumorectomy, Intra Operative Radiotherapy
- Where
- 8 sites in France
- Volunteers
- 66 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer, Breast Reconstruction
Nipple Sparing Mastectomy - Cosmetic Outcomes
The purpose of this study is to observe the cosmetic outcomes, patient satisfaction, and complications after skin sparing mastectomy with preservation of the nipple areolar complex.
- Conditions
- Breast Cancer, Breast Reconstruction, Cosmesis
- Trial name
- NCT01002014
- Testing
- Nipple Sparing Mastectomy
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Rectal Neoplasms
Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias
A multicenter non-inferiority randomized clinical trial to compare Endoscopic treatment (ESD) and Minimally Invasive Laparoscopic Local Surgical Treatment (TAMIS or TEO) for early rectal neoplastic lesions (adenoma \& T1CRC)…
- Trial name
- DSETAMIS2018 (NCT03959839)
- Testing
- ESD, TAMIS, TEO
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Dr. Alberto Herreros de Tejada Echanojáuregui
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab…
- Trial name
- NCT02289209
- Testing
- Reirradiation, MK-3475
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dan Zandberg
Colorectal Cancer
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084773
- Testing
- cetuximab, fluorouracil, neoadjuvant therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced…
- Trial name
- NCT06359275
- Testing
- PD-1, Nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Fudan University